SHR-1701: Clinical Trials

12 trials of SHR-1701, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

8 unknown, 2 completed, 1 not yet recruiting, 1 recruiting. 12 Phase 1, 7 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 112Unknown 8, Completed 2, Not yet recruiting 1, Recruiting 1
Phase 27Unknown 4, Completed 1, Not yet recruiting 1, Recruiting 1

Follow SHR-1701: new trials by email Literature Review of SHR-1701 trials Research Report on SHR-1701

Trials (filtered) newest first · largest first

All 12 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
GnP Combined With SHR-1701 and Apatinib as First-Line Treatment for Metastatic PDAC
SHR-1701, Apatinib, gemcitabine - Metastatic Pancreatic Cancer
Phase 1 / Phase 2RecruitingWest China Hospital452026-09-212026-11-09
SHR1701 Alone or in Combination With SHR2554 in Relapsed or Refractory Classical Hodgkin Lymphoma
SHR2554+ SHR1701, SHR-1701 - Relapsed or Refractory Hodgkin Lymphoma
Phase 1 / Phase 2UnknownChinese PLA General Hospital1002023-06-142023-06-15
Phase Ib/II Study of Almonertinib Combined With SHR-1701 in the Treatment of Relapsed or Advanced Non-small Cell Lung Cancer
Almonertinib combined with SHR-1701, Almonertinib - Relapsed or Advanced Non-small Cell Lung Cancer
Phase 1 / Phase 2Not yet recruitingSuzhou Suncadia Biopharmaceuticals Co., Ltd.1602022-10-012022-08-17
A Trial of SHR-2002 Injection or Combined With Other Anti-cancer Medication in Advanced Malignant Tumors of Patients
SHR-2002 injection、Camrelizumab for Injection, SHR-1316 injection, SHR-1701 injection - Advanced Malignant Tumors
Phase 1UnknownSuzhou Suncadia Biopharmaceuticals Co., Ltd.2402022-02-222022-06-28
SHR-1701 in Combination With Famitinib in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma
SHR-1701, Famitinib - Nasopharyngeal Carcinoma
Phase 1 / Phase 2UnknownJiangsu HengRui Medicine Co., Ltd.302021-09-012021-08-25
A Trial of SHR-1701 in Combination With Famitinib in Patients With Advanced Solid Tumors
SHR-1701, Famitinib - Solid Tumor
Phase 1 / Phase 2UnknownJiangsu HengRui Medicine Co., Ltd.2222021-03-172022-01-26
A Trial of SHR-1701 in Combination With Gemcitabine and Albumin Paclitaxel in Patients With Pancreatic Cancer
SHR-1701 - Pancreatic Cancer
Phase 1 / Phase 2CompletedJiangsu HengRui Medicine Co., Ltd.562020-11-242024-01-11
Phase Ⅰ/Ⅱ Study of SHR2554 in Combination With SHR1701 in Patients With Advanced Solid Tumors and B-cell Lymphomas
SHR2554+SHR1701, SHR1701 - Solid Tumor, Lymphoma
Phase 1 / Phase 2UnknownChinese PLA General Hospital1002020-09-012023-12-12
A Trial of SHR-1701 in Subjects With Advanced Solid Tumors
SHR-1701 - Advanced Solid Tumor
Phase 1CompletedAtridia Pty Ltd.412020-03-312023-02-21
SHR-1701 in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma
SHR-1701, Gemcitabine, Cisplatin - Nasopharyngeal Carcinoma
Phase 1UnknownJiangsu HengRui Medicine Co., Ltd.912020-03-272021-12-21
SHR-1701 in Subjects With Metastatic or Locally Advanced Solid Tumors
SHR-1701 - Solid Tumor
Phase 1UnknownJiangsu HengRui Medicine Co., Ltd.1932019-01-242022-11-08
SHR-1701 in Metastatic or Locally Advanced Solid Tumors
SHR-1701 - Solid Tumor
Phase 1UnknownJiangsu HengRui Medicine Co., Ltd.2062018-11-202021-11-22

Conditions studied

Nasopharyngeal Carcinoma (2)  ·  Neoplasm Metastasis (2)  ·  Pancreatic Neoplasms (2)  ·  Recurrence (2)  ·  Hodgkin Disease (1)  ·  Lymphoma (1)

Sponsors

Jiangsu HengRui Medicine Co., Ltd. (6)  ·  Chinese PLA General Hospital (2)  ·  Suzhou Suncadia Biopharmaceuticals Co., Ltd. (2)  ·  Atridia Pty Ltd. (1)  ·  West China Hospital (1)

Countries

China (10)  ·  Australia (1)

Top investigators

Dan Cao (1)  ·  Jifeng Feng, MD (1)  ·  Lin Shen, MD (1)  ·  Weidong Han, PhD (1)

Results publications

PMID 36280870, PMID 39422697, PMID 41422078